- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03220386
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making (EPICS-6)
July 17, 2017 updated by: Martin Moeckel, Charite University, Berlin, Germany
The study EPICS-6 consists of three study phases.
Emergency Department patients are screened for nasal and pharyngeal colonisation with Methicillin sensitive and Methicillin resistant Staphylococcus aureus (MSSA/MRSA) using a point-of-care (POC)-PCR-testing method (cobas®LIAT®-System, Roche Molecular Systems Inc.)
The first aim of this study is to describe the prevalence of MSSA/MRSA-colonisation in a routine cohort of Emergency Department patients.
The second aim is to determine the impact of POC-guided decolonisation as compared to conventional laboratory testing on in-hospital infection rates with MSSA/MRSA in a pre-post-comparison study.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study EPICS-6 consists of three study phases.
In phase one the novel POC-PCR-testing method for MSSA/MRSA-proof (cobas®LIAT®-System, Roche Molecular Systems Inc.) is technically established and integrated in Emergency Department procedures.
After evaluation of processes and sample handling the second phase of this study assesses the prevalence of positive MSSA/MRSA-POC-testing in the general ED-population and in different risk groups.
Based on the results of the previous study phases, the final phase comprises an interventional pre-post-comparison study.
The interventional study assesses the impact of POC-result guided early decolonisation of MSSA/MRSA-colonized patients on in-hospital infection rates with MSSA/MRSA.
Study Type
Interventional
Enrollment (Anticipated)
1000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Martin Möckel, PhD, MD
- Phone Number: +49 30 450 553 472
- Email: martin.moeckel@charite.de
Study Contact Backup
- Name: Anna Slagman, VMD, MSc
- Phone Number: +49 30 450 665 659
- Email: anna.slagman@charite.de
Study Locations
-
-
-
Berlin, Germany, 13353
- Recruiting
- Charité Universitätsmedizin - Berlin
-
Contact:
- Martin Möckel, Prof. Dr.
- Phone Number: 0049 30 553472
- Email: martin.moeckel@charite.de
-
Contact:
- Anna Slagman, Dr. MSc.
- Phone Number: 004930450553037
- Email: anna.slagman@charite.de
-
Sub-Investigator:
- Dorothee Riedlinger, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 120 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >= 18 years
- Emergency Department (ED) visit in one of the participating EDs
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Emergency Department patients
All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment.
This treatment includes octinidin nasal treatment and skin washings.
|
Patients receive nasal Octinidin treatment and skin washings for five consecutive days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MSSA/MRSA prevalence in a general ED-population
Time Frame: on admission to the ED
|
number of patients with a positive POC-test result for nasal/oral MSSA/MRSA
|
on admission to the ED
|
MSSA/MRSA in-hospital infection rates
Time Frame: at discharge from hospital for up to 90 days after admission
|
number of in-hospital MSSA/MRSA infections in patients with known nasal/oral colonization with MSSA/MRSA.
This outcome measure will be assessed for the time period between admission and discharge from hospital for up to 90 days after study inclusion.
It will be assessed by routine MSSA/MRSA in-hospital testing and the respective test results will be retrieved from the hospital Information system.
|
at discharge from hospital for up to 90 days after admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2017
Primary Completion (ANTICIPATED)
August 1, 2018
Study Completion (ANTICIPATED)
August 1, 2018
Study Registration Dates
First Submitted
May 8, 2017
First Submitted That Met QC Criteria
July 17, 2017
First Posted (ACTUAL)
July 18, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 18, 2017
Last Update Submitted That Met QC Criteria
July 17, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EA1/055/17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus
-
University Hospital TuebingenNot yet recruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of SheffieldRajarata University, Sri LankaUnknown
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...CompletedStaphylococcus AureusUnited States
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Todd C. Lee MD MPH FIDSANot yet recruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | Staphylococcal SepsisCanada
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionKorea, Republic of
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore
Clinical Trials on Decolonization by nasal Octinidin treatment and skin washings
-
3MNew York UniversityCompletedSurgical Site InfectionUnited States
-
Sun Yat-sen UniversityRecruitingNasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative TreatmentChina